# Maxwell's pneumonia drug gets FDA QIDP status

> Maxwell's experimental pneumonia drug receives FDA Qualified Infectious Disease Product designation.
- Title: Maxwell's pneumonia drug gets FDA QIDP status · RuntimeWire
- Summary: Maxwell's experimental pneumonia drug receives FDA Qualified Infectious Disease Product designation. Maxwell Biosciences' preclinical pneumonia drug received…
- Keywords: maxwell biosciences, pneumonia drug, fda qidp, preclinical, regulatory path, experimental drug, technology, Maxwell's, pneumonia, drug, gets, FDA
- Source: RuntimeWire — https://runtimewire.com/article/maxwell-pneumonia-drug-qidp-preclinical
- Author: RuntimeWire
- Published: 2026-10-25T08:14:36.092+00:00
- Read time: 1 min
- Topics: maxwell biosciences, pneumonia drug, fda qidp, preclinical, regulatory path, experimental drug, technology, ai
## FDA QIDP designation
Maxwell Biosciences' experimental pneumonia drug received FDA Qualified Infectious Disease Product status in May.
## Preclinical status
The candidate remains preclinical and has not been tested in people.
## Regulatory development path
The designation gives Maxwell a regulatory development path.
## Key takeaway

Maxwell Biosciences' preclinical pneumonia drug received FDA QIDP status in May, advancing its regulatory path.